North America Cell-based Assays Market Report 2022: Featuring Becton, Dickinson, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche & More - ResearchAndMarkets.com

The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, January 13, 2023
Information
Tags: 
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Disease, National Cancer Institute, Non-Hodgkin lymphoma, Kidney, Prostate cancer, Drug development, Biomedical Research, Melanoma, Country, Colon, Pancreatic cancer, Cancer, Skin, Endometrial cancer, Lung, Thyroid cancer, Drug discovery, Bladder cancer, Breast cancer, Liver cancer, GPCR, Comprehension, Product-service system, Leukemia, Medicinal plants
Geotags: 
NORTH AMERICA, UNITED STATES, US
⚠ generated by AI ↴
Organisation: 
RESEARCH AND MARKETS, RESEARCHANDMARKETS.COM
Summary
Key Points: 
  • The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • These assays include cell viability assays, cell proliferation assays, and GPCR assays.
  • These high-throughput assays speed up the process of drug discovery by giving the most promising candidate in the biological context that matters the most.
  • The US market dominated the North America Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $7.2 billion by 2028.


The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The North America Cell-based Assays Market should witness market growth of 7.5% CAGR during the forecast period (2022-2028).

These assays include cell viability assays, cell proliferation assays, and GPCR assays. These high-throughput assays speed up the process of drug discovery by giving the most promising candidate in the biological context that matters the most.

Drug development has progressed from a limited target-based screening in a basic cell-based assay that had little physiological relevance to multicellular cell-based biochemical and functional assays in disease-relevant platforms.

Cell-based assays for each stage of the drug development process have been developed in recent years to offer a deeper comprehension of the intricate interactions to researchers that take place between the networks and pathways that are a part of these cellular processes. Assays may be built to best simulate the disease state if the patient has access to a variety of cell types and are able to use both existing and innovative technologies.

This will lead to increased performance in translational research. In both biomedical research and drug discovery screening applications, cellular assays, also known as cell-based assays, can be utilized to efficiently assess biological activity, cytotoxicity, biochemical processes, and off-target interactions.

Cancer has a significant impact on society throughout the United States. Cancer statistics reflect what occurs in big populations and provide a temporal picture of the societal burden of cancer. According to the National Cancer Institute, In the United States, an anticipated 1,806,590 new instances of cancer were identified in 2020, and 606,520 people died due to the disease. Breast cancer, colon and rectum cancer, lung and bronchus cancer, bladder cancer, prostate cancer, melanoma of the skin, kidney and renal pelvis cancer, non-Hodgkin lymphoma, endometrial cancer, leukemia, thyroid cancer, pancreatic cancer, and liver cancer are the most prevalent types of cancer.

The US market dominated the North America Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $7.2 billion by 2028. The Canada market is experiencing a CAGR of 10% during (2022-2028). Additionally, The Mexico market would exhibit a CAGR of 9% during (2022-2028).

Scope of the Study

By Application

  • Drug Discovery
  • Basic Research
  • Others

By End-user

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)

By Products & Services

  • Assay Kits
  • Reagents
  • Microplates
  • Probes & Labels
  • Instruments & Software
  • Cell Lines

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Competition Analysis - Global

Chapter 4. North America Cell-based Assays Market by Application

Chapter 5. North America Cell-based Assays Market by End-use

Chapter 6. North America Cell-based Assays Market by Products & Services

Chapter 7. North America Cell-based Assays Market by Country

Chapter 8. Company Profiles

Companies Mentioned

  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Corning Incorporated
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Lonza Group AG
  • Merck Group
  • Promega Corporation
  • Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ox3c4v

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Copyright: 
Copyright Business Wire 2023